Organization · Venture Capital
BioStar Capital
BioStar Capital is a Michigan-based venture capital firm that specializes in transformative medical technologies, particularly in cardiology and orthopedics. The firm integrates healthcare professionals into its investment strategy to enhance clinical validation and strategic advisement.
Overview
What BioStar Capital does
What BioStar Capital is
BioStar Capital is a Michigan-based venture capital firm that specializes in transformative medical technologies, particularly in cardiology and orthopedics. The firm integrates healthcare professionals into its investment strategy to enhance clinical validation and strategic advisement.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2005
- Approximate age
- About 21 years
- Structured capabilities
- Funder
- Last reviewed
- March 30, 2026
Official channels
Find BioStar Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
BioStar Capital as a funder
Investment thesis
BioStar Capital focuses on transformative medical technologies that benefit patients and physicians, leveraging a physician-integrated General Partner model for strategic advisement.
Focus narrative
BioStar Capital invests in innovative medical technologies that address unmet patient needs, with a particular emphasis on cardiovascular and orthopedic sectors. Their investment strategy includes 'smart' devices, robotics, minimally invasive solutions, cost-reduction technology, and outpatient-center technology.
Value beyond capital
BioStar Capital adds value to its portfolio companies through a unique physician-integrated General Partner model, providing clinical validation and strategic advisement from leading medical professionals. This approach enhances the development and market entry of innovative medical technologies.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
Focus and fit
- Stages
- Seed · Friends and Family · Series A · Series B · Growth Equity
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 50
- Recorded notable exits
- Transcatheter renal denervation for hypertension, Pulsatile Intravascular Lithotripsy (PIVL) for calcified arteries, Passive implant for treating pulmonary hypertension, Catheter-based nerve sensing and ablation in a single procedure, Pulsed field ablation (PFA) for ventricular tachycardia (VT), and Robotically manufactured polymer heart valve, plus 6 more
Portfolio context
BioStar Capital's portfolio includes notable companies such as Ablative Solutions, which focuses on transcatheter renal denervation for hypertension; AVS Pulse, developing pulsatile intravascular lithotripsy for calcified arteries; and Foldax, which manufactures robotically produced polymer heart valves. Other portfolio companies include Senseonics, known for long-term continuous glucose monitoring, and Versa Vascular, innovating percutaneous tricuspid valve repair without surgery.
Common questions
What to know about BioStar Capital
Upseed classifies BioStar Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 30, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.